

NIH/NIA Budget Update



NIA Appropriations - FY12 Enacted, FY13 President's Budget


Current versus Constant, FY03 Base Year

**Difference from
FY2003**

**In Current
Dollars:
\$109.1M
Increase**


**In Constant
Dollars:
\$206.7M
Decrease**

**20.8% decrease
FY2003-2013 Est**




	FY03	FY04	FY05	FY06	FY07	FY08	FY09	FY10	FY11	FY12	FY13 Est
Series1	993.6	1,021.4	1,045.3	1,036.6	1,045.5	1,051.0	1,079.0	1,110.2	1,100.5	1,102.1	1,102.7
Series2	993.6	984.9	970.2	919.5	893.5	858.0	856.1	856.0	825.3	808.6	786.9

Proportion of Total NIH Budget, FY2011 RPGs are 51%




Proportion of Total NIA Budget, FY2011 RPGs are 64%



NIA and NIH **RPG** Success Rates 2008 to 2012

	2008	2009	2010	2011	2012
NIH	21.8%	20.6%	20.6%	17.7%	17.6%
NIA	20.4%	17.5%	14.5%	16.1%	15.5%

NIH R01 Success Rates for FY2012



Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR)

- **Goal**

The overall goal of the GEMSSTAR Program is to provide support for early stage clinician-scientists to establish a track record in aging research. The GEMSSTAR award is targeted to early faculty members who have recently completed their clinical training in any medical or surgical specialty and are embarking on a career in clinical aging research in their specialty area. The award is intended to offer support in a particularly vulnerable time in a new clinical faculty member's career.

Keep an eye out for a new announcement about this award

RFA

- Change in Page Limits
- Submission Date - June 11
- Electronic submission – ASSIST
- Changes from Previous RFAs
 - Page limits
 - Clinical Core
 - Outreach core

Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention

May 14-15, 2012

National Institutes of Health

U.S. Department of Health & Human Services

Bethesda, MD




Alzheimer's Disease Research Summit Recommendations

- **Session 1:** Interdisciplinary Approach to Discovering and Validating the Next Generation of Therapeutic Targets for AD
- **Session 2:** Challenges in Preclinical Therapy Development
- **Session 3:** Whom to Treat, When to Treat, and What Outcomes to Measure
- **Session 4:** Drug Repurposing and Combination Therapy
- **Session 5:** Nonpharmacological Interventions
- **Session 6:** New Models of Public Private Partnerships

<http://www.nia.nih.gov/newsroom/announcements/2012/05/alzheimers-disease-research-summit-offers-research-recommendations>

MAY 1-2

2013



ALZHEIMER'S DISEASE-RELATED DEMENTIAS: Research Challenges and Opportunities

Sponsored by the
National Institute of Neurological Disorders and Stroke
in cooperation with:

- National Institute on Aging
- Alliance for Aging Research, ACT-AD
- Alzheimer's Association
- Association for Frontotemporal Degeneration
- USAgainst Alzheimer's

www.ninds.nih.gov/ADRelatedDementias2013